Inflation, Supply Chain And Private Label Pressures: Consumer Health Leaders Talk ‘Big Picture’ Challenges

OTC drug and dietary supplement companies continue to face significant economic and competitive issues in what continues to be a highly volatile operating environment. Here we’ve culled takes from top execs at Sanofi, Bayer, J&J, P&G and other leading players, provided during recent sales and earnings presentations.

Positive, young woman looking through a spyglass in front of a blackboard as a crossroad arrows splitted in three different ways. Choosing between up, down and ahead. Difficult decision concept.
• Source: Shutterstock

Lots of talk of macroeconomic headwinds in consumer health companies' quarterly earnings calls of late. CEOs and other top execs at Sanofi, Bayer, Reckitt, Prestige Consumer Healthcare, Johnson & Johnson, Procter & Gamble, Abbott, Church & Dwight, Herbalife, and Bausch & Lomb provided commentary on challenges and what lies ahead. Highlights compiled by HBW Insight.

Julie van Ongevalle

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Supply Chain

More from HBW Insight